Jean-Pierre Lindenmayer, MD

Letter to the Editor

Dr. Lindenmayer Replies

January 15, 2008

Original Research

A Randomized Controlled Trial of Olanzapine Versus Haloperidol in the Treatment of Primary Negative Symptoms and Neurocognitive Deficits in Schizophrenia

March 15, 2007

Letter to the Editor

Tolerability of High-Dose Aripiprazole in Treatment-Refractory Schizophrenic Patients

July 14, 2006

Letter to the Editor

Clozapine Augmentation With Aripiprazole for Negative Symptoms

April 15, 2006

Original Research

Dosing of Quetiapine in Schizophrenia: How Clinical Practice Differs From Registration Studies

December 15, 2005

Letter to the Editor

Reply to "Injection Site Pain With Long-Acting Risperidone"

May 15, 2005

Letter to the Editor

Measuring Efficacy of Polypharmacy in Schizophrenic Inpatients

August 16, 2004

Original Research

Safety and Efficacy of Long-Acting Risperidone in Schizophrenia: A 12-Week, Multicenter, Open-Label Study in Stable Patients Switched From Typical and Atypical Oral Antipsychotics

August 16, 2004

Article

Epidemiology of Cardiovascular Disease and Major Metabolic Risk Factors

May 1, 2004

Article

Antipsychotic Drugs, Insulin Resistance, Hyperglycemia, and Diabetes Mellitus

May 1, 2004

Article

Treatment Recommendations for Psychiatrists

May 1, 2004

Article

Schizophrenia, Metabolic Disorders, and Cardiovascular Disease

May 1, 2004